Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 15/20 | 0.45 |
| ▸ | RHOC | P08134 | 3/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444264 | 0.95 | EPHX2 (0.49) | RHOARHOCCXCR3EPHX2CNR1 | |
| SCHEMBL12006206 | 0.94 | RHOA (0.44) | RHOARHOCCXCR3EPHX2CNR1 | |
| SCHEMBL12004594 | 0.83 | CXCR3 (0.44) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL6863162 | 0.80 | CXCR3 (0.42) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL6864138 | 0.80 | RHOC (0.43) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL6863915 | 0.80 | RHOC (0.43) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL6863467 | 0.80 | RHOC (0.43) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL12005749 | 0.80 | RHOC (0.43) | RHOARHOCCXCR3EPHX2USP30 | |
| SCHEMBL22019439 | 0.79 | CXCR3 (0.46) | RHOARHOCCXCR3EPHX2 | |
| SCHEMBL6863832 | 0.79 | CXCR3 (0.42) | RHOARHOCCXCR3EPHX2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | RHOA 1738/4885RHOC 1928/4885CXCR3 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.